clinical trial · NCT01617967
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
TTR-mediated AmyloidosisPatisiran
brief summary
This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
started
May 1, 2012
primary completion
Oct 1, 2013
completion
Jan 1, 2014
last updated
Apr 19, 2024
official title
A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol